Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
- Conditions
- Migraine Without AuraMigraine With AuraMigraine
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05337254
- Locations
- 🇺🇸
Quotient Sciences Miami Inc., Miami, Florida, United States
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
- Conditions
- Migraine With AuraMigraine Without AuraMigraine
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 1591
- Registration Number
- NCT04940390
- Locations
- 🇺🇸
MD First Research, Chandler, Arizona, United States
🇺🇸Elite Clinical Studies, Phoenix, Arizona, United States
🇺🇸Alliance For Multispecialty Research, Norfolk, Virginia, United States
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
- Conditions
- MigraineMigraine With AuraMigraine Without Aura
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 482
- Registration Number
- NCT04406649
- Locations
- 🇺🇸
WR-PRI, Newport Beach, California, United States
🇺🇸Collaborative Neuroscience, Long Beach, California, United States
🇺🇸Downtown LA Research, Los Angeles, California, United States
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
- Conditions
- MigraineMigraine With AuraMigraine Without Aura
- Interventions
- Drug: Placebos
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 1201
- Registration Number
- NCT03901482
- Locations
- 🇺🇸
Accel Clinical - Birmingham, Birmingham, Alabama, United States
🇺🇸Alabama Clinical Therapeutics, Birmingham, Alabama, United States
🇺🇸Alea Research, Phoenix, Arizona, United States
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
- Conditions
- MigraineMigraine With AuraMigraine Without Aura
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT03874832
- Locations
- 🇺🇸
Quotient Sciences Miami Inc., Miami, Florida, United States